Moreover, the benefits observed in frail patients and the potential renoprotective effects suggest that GLP-1 RAs may be particularly valuable in older patients and those with CKD, two populations that often present challenges in diabetes management. The gene discussed is GLP1R; the disease is chronic kidney disease.